A continuous subcutaneous insulin pump using rapid‐acting insulin analogues was initiated at the third day after the diagnosis of T1D 0.3 IE/h of insulin was given initially and gradually increased to 1 IE/h. The gene discussed is INS; the disease is type 1 diabetes mellitus.